HC Wainwright Increases Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target to $85.00

Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price objective upped by equities researchers at HC Wainwright from $80.00 to $85.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 30.63% from the company’s previous close. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals’ Q1 2026 earnings at $1.63 EPS and Q3 2027 earnings at ($1.31) EPS.

A number of other research firms have also recently commented on ARWR. Bank of America raised their target price on Arrowhead Pharmaceuticals from $42.00 to $62.00 and gave the company a “buy” rating in a research note on Monday. Piper Sandler raised their target price on shares of Arrowhead Pharmaceuticals from $45.00 to $70.00 and gave the company an “overweight” rating in a report on Wednesday, November 19th. Chardan Capital restated a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Monday. Royal Bank Of Canada boosted their target price on Arrowhead Pharmaceuticals from $45.00 to $52.00 and gave the company an “outperform” rating in a research report on Wednesday, November 19th. Finally, The Goldman Sachs Group raised their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $48.00 and gave the stock a “neutral” rating in a research note on Thursday, November 20th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $53.33.

Arrowhead Pharmaceuticals Stock Performance

Shares of Arrowhead Pharmaceuticals stock opened at $65.07 on Tuesday. Arrowhead Pharmaceuticals has a twelve month low of $9.57 and a twelve month high of $66.23. The company has a quick ratio of 4.86, a current ratio of 4.86 and a debt-to-equity ratio of 0.43. The company’s fifty day moving average is $40.78 and its 200 day moving average is $26.90. The stock has a market cap of $8.84 billion, a price-to-earnings ratio of -813.27 and a beta of 1.28.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, insider James C. Hamilton sold 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $35.00, for a total transaction of $700,000.00. Following the sale, the insider owned 212,122 shares of the company’s stock, valued at $7,424,270. This trade represents a 8.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Mauro Ferrari sold 8,750 shares of the company’s stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $56.39, for a total value of $493,412.50. Following the transaction, the director directly owned 68,764 shares of the company’s stock, valued at approximately $3,877,601.96. The trade was a 11.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 43,750 shares of company stock valued at $1,643,413. 4.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. iSAM Funds UK Ltd purchased a new position in shares of Arrowhead Pharmaceuticals during the third quarter worth $29,000. Virtus Advisers LLC purchased a new position in Arrowhead Pharmaceuticals in the second quarter worth approximately $34,000. Salomon & Ludwin LLC acquired a new position in shares of Arrowhead Pharmaceuticals during the third quarter worth $34,000. Nisa Investment Advisors LLC increased its holdings in shares of Arrowhead Pharmaceuticals by 75.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 1,308 shares during the last quarter. Finally, Federated Hermes Inc. purchased a new stake in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth approximately $52,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.